BidaskClub lowered shares of Strongbridge Biopharma (NASDAQ:SBBP) from a hold rating to a sell rating in a report released on Tuesday morning.
Several other research firms have also commented on SBBP. Zacks Investment Research raised Strongbridge Biopharma from a sell rating to a hold rating in a report on Friday, April 6th. Cantor Fitzgerald set a $14.00 target price on Strongbridge Biopharma and gave the stock a buy rating in a report on Thursday, April 5th. ValuEngine raised Strongbridge Biopharma from a sell rating to a hold rating in a report on Wednesday, May 2nd. Finally, HC Wainwright reaffirmed a buy rating on shares of Strongbridge Biopharma in a report on Friday, May 11th. Two analysts have rated the stock with a sell rating, one has given a hold rating and four have assigned a buy rating to the stock. The company currently has an average rating of Hold and an average target price of $12.81.
Shares of Strongbridge Biopharma opened at $6.00 on Tuesday, Marketbeat Ratings reports. The stock has a market capitalization of $266.38 million, a PE ratio of -4.14 and a beta of 0.91. Strongbridge Biopharma has a 52-week low of $5.20 and a 52-week high of $9.25. The company has a debt-to-equity ratio of 41.16, a current ratio of 8.90 and a quick ratio of 8.74.
Strongbridge Biopharma (NASDAQ:SBBP) last posted its earnings results on Thursday, May 10th. The biotechnology company reported ($0.66) EPS for the quarter, missing the consensus estimate of ($0.41) by ($0.25). The company had revenue of $3.87 million for the quarter, compared to analyst estimates of $3.25 million. Strongbridge Biopharma had a negative return on equity of 1,224.30% and a negative net margin of 1,032.62%. equities analysts predict that Strongbridge Biopharma will post -1.94 earnings per share for the current fiscal year.
A number of institutional investors have recently bought and sold shares of SBBP. Oppenheimer & Co. Inc. acquired a new stake in Strongbridge Biopharma in the first quarter valued at approximately $119,000. Citadel Advisors LLC acquired a new stake in Strongbridge Biopharma in the first quarter valued at approximately $166,000. Paloma Partners Management Co acquired a new stake in Strongbridge Biopharma in the fourth quarter valued at approximately $152,000. Barclays PLC grew its holdings in Strongbridge Biopharma by 429.8% in the first quarter. Barclays PLC now owns 21,109 shares of the biotechnology company’s stock valued at $188,000 after purchasing an additional 17,125 shares during the period. Finally, Granite Investment Partners LLC acquired a new stake in Strongbridge Biopharma in the first quarter valued at approximately $215,000. 67.69% of the stock is currently owned by hedge funds and other institutional investors.
Strongbridge Biopharma Company Profile
Strongbridge Biopharma plc, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases with unmet needs. The company's commercial products include Keveyis, an oral carbonic anhydrase inhibitor for treating hyperkalemic, hypokalemic, and related variants of primary periodic paralysis in the United States; and Macrilen, an oral growth hormone secretagogue receptor agonist for use in the diagnosis of patients with adult growth hormone deficiency in the United States and Canada.
Receive News & Ratings for Strongbridge Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Strongbridge Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.